Invention Grant
- Patent Title: Use of anagrelide for treating cancer
-
Application No.: US15538326Application Date: 2015-12-22
-
Publication No.: US11324746B2Publication Date: 2022-05-10
- Inventor: Stephen Damment , Richard Franklin , Jorge D. Erusalimsky
- Applicant: Arovella Therapeutics Limited
- Applicant Address: AU Osborne Park
- Assignee: Arovella Therapeutics Limited
- Current Assignee: Arovella Therapeutics Limited
- Current Assignee Address: AU Osborne Park
- Agency: Haug Partners LLP
- Priority: GB1422978 20141222
- International Application: PCT/GB2015/054116 WO 20151222
- International Announcement: WO2016/102952 WO 20160630
- Main IPC: A23K50/10
- IPC: A23K50/10 ; A23K20/158 ; A61K31/519 ; A61K47/26
Abstract:
The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
Public/Granted literature
- US20170360793A1 USE OF ANAGRELIDE FOR TREATING CANCER Public/Granted day:2017-12-21
Information query
